Moderna cuts costs and preps cancer data while COVID fades
- Moderna has five approved products, including the newly approved mFLUSIVA for seasonal flu.
- Management raised 2026 revenue growth guidance to 15 to 25 percent and lowered cost targets.
- A Phase 3 melanoma trial showed a 42 percent drop in the risk of recurrence or death.
- The norovirus vaccine program halted new enrollment, adding pipeline uncertainty.
- COVID vaccines still drive almost all near-term product sales despite fading demand.
A platform under pressure
Moderna is trying to turn its COVID windfall into a lasting biotech business. The bull case relies on the mRNA platform producing new products. The company now has five approved vaccines, and Q3 2026 offered a positive signal as management raised full-year revenue growth guidance to a range of 15 to 25 percent. The company also lowered its 2026 cash cost guidance to $3.8 billion.
The newest commercial win is mFLUSIVA, a seasonal flu vaccine approved in the U.S. and Canada. If it gains use alongside mCOMBRIAX in upcoming respiratory seasons, Moderna can prove that its platform sells more than stand-alone COVID shots. A major boost to the bull case came from a Phase 3 melanoma trial, which showed a 42 percent reduction in the risk of recurrence or death.
The bear case is still hard to ignore. Q2 2026 product sales were extremely weak at $94 million, and the RSV vaccine added only $3 million. Meanwhile, the norovirus vaccine halted enrollment for an additional cohort, introducing delays and competitive questions.
The next year is mostly about proof. Investors will watch for a melanoma therapy submission targeted for late 2026, data from a propionic acidemia trial, and regulatory feedback on U.S. filing strategies for the flu and COVID combo vaccine.
Selling shots while funding science
Moderna makes money by selling vaccines based on messenger RNA, or mRNA. mRNA is a set of instructions that tells cells to make a target protein, so the immune system can learn what to fight.
Today the business is still mostly a respiratory vaccine company. Its approved products are Spikevax for COVID, mNEXSPIKE as a next-generation COVID shot, mRESVIA for RSV, mCOMBRIAX for flu plus COVID, and mFLUSIVA for seasonal influenza.
The model works only if new products can replace shrinking COVID demand. That is why cost control matters. Management recently lowered 2026 cash cost guidance to approximately $3.8 billion, reflecting operational improvements in research and manufacturing. A recent $2.6 billion net convertible debt raise further protects the balance sheet.
Moderna is also using partners where it makes sense. Its Recordati deal for mRNA-3927, a propionic acidemia therapy, lets Moderna lead clinical development while Recordati would help with global commercialization if approved.
Five products, many bets
Spikevax
Spikevax is Moderna's original COVID-19 vaccine. Sales have moved from a pandemic surge to a smaller seasonal market.
mNEXSPIKE
mNEXSPIKE is the next-generation COVID vaccine launched in Q3 2025. Moderna says it became its leading U.S. retail channel product in 2025.
mRESVIA
mRESVIA is the RSV vaccine. It is approved for adults 60 and older, but early commercial sales have been minimal.
mCOMBRIAX
mCOMBRIAX combines flu and COVID protection in one shot. It is approved in Europe and Canada.
mFLUSIVA
mFLUSIVA is a seasonal influenza vaccine. It received approval in the U.S. and Canada, becoming the fifth commercial product.
mRNA-4157 (Intismeran)
mRNA-4157 is an individualized cancer therapy partnered with Merck. Phase 3 melanoma data showed a significant reduction in recurrence or death.
mRNA-3927 rare disease therapy
mRNA-3927 targets propionic acidemia, a rare disease. Its registrational study has reached target enrollment, with data expected in late 2026.
Still a COVID-heavy mix
Moderna reports as one operating segment. The product-sales mix shown here is from Q2 2026 net product sales of $94 million, made up of $91 million from COVID vaccines and $3 million from mRESVIA.
What could break the story
New vaccines do not sell
High impact · High oddsThe biggest risk is commercial. mRESVIA entered an RSV market already served by two larger competitors, and early sales were weak. mCOMBRIAX and mFLUSIVA may face the same problem if doctors and pharmacies stick with older alternatives.
Losses drain the cash runway
High impact · Medium oddsModerna is cutting costs, but the company is still losing a lot of money. The company recently raised convertible debt to bolster cash. If revenue growth stalls, cost cuts may not be enough to reach profitability.
The pipeline misses again
High impact · Medium oddsThe norovirus vaccine recently halted enrollment for an additional cohort, mirroring an earlier failure in the CMV vaccine trial. The remaining late-stage bets now carry more weight. A miss in melanoma or rare disease would hurt the bull case.
Pricing rules cut vaccine revenue
Medium impact · Medium oddsModerna warned that U.S. drug pricing reforms could hurt revenue. These models can tie U.S. prices to lower prices in other countries. That matters because the U.S. is often a key profit pool for vaccines and biotech drugs.
In one breath
What does Moderna actually sell now?
Moderna sells COVID vaccines, an RSV vaccine, a seasonal flu vaccine, and a flu plus COVID combo vaccine. COVID vaccines still make up nearly all product sales based on recent quarters.
Why is Moderna still losing money?
COVID demand is much lower than during the pandemic, while Moderna still spends heavily on research, trials, and new launches. The company is actively cutting cash costs to manage these losses.
What is Moderna's biggest upcoming catalyst?
The clearest near-term catalyst is a planned late 2026 regulatory submission for Intismeran, an individualized cancer therapy for melanoma. Investors will also watch late-stage clinical data in rare diseases.
Is Moderna only a COVID company?
No, but it still depends heavily on COVID vaccine sales today. The investment case is about whether flu, combo vaccines, cancer therapy, and rare disease programs can create a new revenue base.
Sources and research notes
This page combines Finn's company research with public filings and other cited materials. The thesis is reviewed when material company information changes; Finn Scores use the latest available scoring data.
- Thesis reviewed
- November 8, 2026
- Score data
- November 15, 2026
- Reviewed by
- Shivam Bharuka
Comparable Biotechnology companies
Companies near Moderna, Inc. in Finn's Biotechnology industry ranking.

